Craig B.  Reynolds net worth and biography

Craig Reynolds Biography and Net Worth

Director of Masimo
Craig B. Reynolds is an Independent Director of Masimo Corp. Mr. Reynolds is currently Chief Executive Officer and a director of Cereve, Inc., a medical company engaged in resolving insomnia issues. Prior to joining Cereve, Mr. Reynolds served as Chief Operating Officer of Philips-Respironics Home Health Solutions (“Philips-Respironics”), a subsidiary of Philips, from 2008 to 2010. Prior to Philips-Respironics, Mr. Reynolds was the Chief Operating Officer and a board member of Respironics, Inc., a company that develops, manufactures and markets medical devices worldwide, from 1998 to 2008. From 1993 to 1998, Mr. Reynolds was with Healthdyne Technologies, Inc., a medical device company, serving for five years as Chief Executive Officer and director. From 1981 through 1992, Mr. Reynolds was with Healthdyne, Inc. in the positions of Executive V.P. (1981 to 1983), President of Healthdyne Cardiovascular Division (1984 to 1985) and President of Healthdyne Homecare Division (1986 to 1992). From 2008 through 2014, Mr. Reynolds served as a director of Symmetry Medical, Inc., most recently as Chairman of the Board. He also served as Chairman of the Board of Symmetry Surgical, Inc. from 2014 through 2016. Mr. Reynolds earned his B.S. in Industrial Management from the Georgia Institute of Technology and his M.B.A. from Georgia State University.

What is Craig B. Reynolds' net worth?

The estimated net worth of Craig B. Reynolds is at least $1.93 million as of January 11th, 2021. Mr. Reynolds owns 14,300 shares of Masimo stock worth more than $1,927,211 as of April 19th. This net worth estimate does not reflect any other assets that Mr. Reynolds may own. Learn More about Craig B. Reynolds' net worth.

How do I contact Craig B. Reynolds?

The corporate mailing address for Mr. Reynolds and other Masimo executives is 52 DISCOVERY, IRVINE CA, 92618. Masimo can also be reached via phone at (949) 297-7000 and via email at [email protected]. Learn More on Craig B. Reynolds' contact information.

Has Craig B. Reynolds been buying or selling shares of Masimo?

Craig B. Reynolds has not been actively trading shares of Masimo during the past quarter. Most recently, Craig B. Reynolds sold 10,000 shares of the business's stock in a transaction on Monday, January 11th. The shares were sold at an average price of $279.74, for a transaction totalling $2,797,400.00. Following the completion of the sale, the director now directly owns 14,300 shares of the company's stock, valued at $4,000,282. Learn More on Craig B. Reynolds' trading history.

Who are Masimo's active insiders?

Masimo's insider roster includes H. Cohen (Director), Jon Coleman (Insider), Joe Kiani (CEO), Tao Levy (EVP), Thomas McClenahan (EVP), Adam Mikkelson (Director), Bilal Muhsin (COO), Craig Reynolds (Director), Anand Sampath (EVP), and Micah Young (CFO). Learn More on Masimo's active insiders.

Are insiders buying or selling shares of Masimo?

During the last twelve months, Masimo insiders bought shares 1 times. They purchased a total of 6,365 shares worth more than $1,000,323.40. The most recent insider tranaction occured on May, 25th when CEO Joe E Kiani bought 6,365 shares worth more than $1,000,323.40. Insiders at Masimo own 9.7% of the company. Learn More about insider trades at Masimo.

Information on this page was last updated on 5/25/2023.

Craig B. Reynolds Insider Trading History at Masimo

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/11/2021Sell10,000$279.74$2,797,400.0014,300View SEC Filing Icon  
10/27/2020Sell10,000$250.00$2,500,000.0014,300View SEC Filing Icon  
10/12/2020Sell20,000$240.11$4,802,200.0014,300View SEC Filing Icon  
See Full Table

Craig B. Reynolds Buying and Selling Activity at Masimo

This chart shows Craig B Reynolds's buying and selling at Masimo by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Masimo Company Overview

Masimo logo
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $134.77
Low: $133.69
High: $137.44

50 Day Range

MA: $135.66
Low: $126.49
High: $146.85

2 Week Range

Now: $134.77
Low: $75.22
High: $198.00

Volume

352,900 shs

Average Volume

576,976 shs

Market Capitalization

$7.13 billion

P/E Ratio

89.25

Dividend Yield

N/A

Beta

0.97